

VIRTUAL EVENT SERIES

# DRUG DISCOVERY & DEVELOPMENT

FEBRUARY 21, 2024



Date	Time	Track	Presentation Title	Speaker
21-Feb	06:00 - 07:00 AM	Advancing the Art: Improving Drug Discovery Methodology	Enhancing Synthesis Workflows Through Computer-Assisted Retrosynthesis with Live Q&A	Dr. Ewa Gajewska, PhD Head of Product Management SYNTHIA™ Retrosynthesis Software, Digital Chemistry
21-Feb	06:00 - 07:00 AM	Biomarker Applications	Leveraging Expert-Curated Knowledge from COSMIC and QIAGEN to Avoid Pitfalls, Qualify Candidate Drug Targets, and Accelerate Early Discovery	Kyle Nilson, PhD Field Software Trainer, QIAGEN Digital Insights
21-Feb	07:30 - 08:30 AM	Biomarker Applications	Keynote Presentation: High-Throughput Interrogation of the Tumor Microenvironment Using Digital Image Analysis	Harry Nunns Senior Scientist, NeoGenomics Laboratories
21-Feb	09:00 - 10:00 AM	Advancing the Art: Improving Drug Discovery Methodology	Keynote Presentation: The Clinical Progression to Optimal Outcomes for Beta-Lactam Antibiotics: from Prolonging Infusions to Precision Dosing	Marc H. Scheetz, PharmD, MSc, FCCP, FCP Associate Dean of Research and Professor, College of Pharmacy, Professor, College of Graduate Studies, Departments of Pharmacology and Biomedical Sciences, Director, Pharmacometrics Center of Excellence, Northwestern University
21-Feb	10:30 - 12:00 PM	Emerging Modalities in Drug Discovery and Preclinical Development Emerging Assays	Keynote Presentation: The Integration of Interoceptive Signals and Defensive Behaviors via Neurohypophysial Hormones	Joanna Dabrowska, PhD, PharmD Associate Professor, Center for the Neurobiology of Stress Resilience and Psychiatric Disorders, Department of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science
21-Feb	11:30 - 12:30 PM	Emerging Modalities in Drug Discovery and Preclinical Development	Automating Liver Perfusion to Isolate Primary Hepatocytes with Live Q&A	Philipp Schlärmann, PhD Global Product Manager for Sample Preparation, Miltenyi Biotec B.V. & CO. KG
21-Feb	11:30 - 12:30 PM	New Methods in Pharmacogenomics: PGX of GPCRs	Multiplexed Mapping of the GPCR-RAMP Interactome	Jochen Schwenk, PhD Professor in Translational Proteomics, KTH Royal Institute of Technology

21-Feb	12:00 - 01:00 PM	Advancing the Art: Improving Drug Discovery Methodology	Challenging the 'Art' of SPR with Live Q&A	Stuart Knowling, PhD Senior Scientist, Application Development
21-Feb	12:00 - 01:00 PM	Emerging Modalities in Drug Discovery and Preclinical Development	The Long and Short of mRNA Production	Daniel Dixon Field Applications Scientist Nucleic Acid Therapeutics Thermo Fisher Scientific
21-Feb	01:00 - 02:00 PM	Emerging Modalities in Drug Discovery and Preclinical Development	Accelerate Discovery and Development by Optimizing the Protein Engineering Workflow	Claudia Chiocchini Manager, Research and Development
21-Feb	01:00 - 02:00 PM	ADVANCING THE ART: IMPROVING DRUG DISCOVERY METHODOLOGY	Panel Presentation: Revolutionize Your Lab Work with Connected Electronic Pipettes with Live Q&A	Joni Åke Product Manager Liquid Handling Sandra Söderholm Application Development Scientist Liquid Handling
21-Feb	On Demand	New Methods in Pharmacogenomics	A Stem Cell-based Approach to Lung Cancer	Huanhuan Joyce Chen, PharmD PhD Assistant Professor, The Pritzker School of Molecular Engineering, The Ben May Department for Cancer Research, The Committee on Development, Regeneration, and Stem Cell Biology, The University of Chicago
21-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	An In Vitro Pre-Clinical MPS Model for Metabolic Associated Steatohepatitis for Drug Efficacy	Christiana Skarlatopoulou Scientist, CN-Bio
21-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	CNS Delivery in Drug Development and Toxicology: Best Practices and Recent Advances	Simon Authier, DVM, MBA, PhD, DSP Principal Director, Scientific Operations and Veterinary Science, Charles River
21-Feb	On Demand	Advancing the Art: Improving Drug Discovery Methodology	Development of an Interconnected Gut-Liver Model of Primary Human Origin Using Microphysiological Systems (MPS) for ADME Studies	Hailey Sze Scientist, CN-Bio Innovations
21-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	Diosgenin Induces Anti-Hyperalgesic Effect via Antagonism of Transient Receptor Potential Vanilloid 1 in Pain Model	Dr. Md. Mahbubur Rahman, DVM, PhD Veterinarian and Biomedical Research Professor, College of Medicine, Gachon University
21-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	Epithelial-Mesenchymal Transition in the Crosshairs: Novel Treatments to Kill Drug Resistant, Metastatic Cells in Cancer	Cai Roberts, PhD Assistant Professor, Pharmacology, Midwestern University

21-Feb	On Demand	Advancing the Art: Improving Drug Discovery Methodology	Picodroplets Enabling High Throughput Single Cell Screening and Isolation	Romina Durigon, PhD Senior Field Application Scientist, Sphere Fluidics Limited
21-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	Proliferation Biomarkers in Drug Discovery and Development, The Immunoassay of Thymidine Kinase 1	Martin Shaw Business Development, AroCell AB
21-Feb	On Demand	Biomarker Applications	Unveiling the Therapeutic Potential of Two Sister Flavonoids Using Omics Based Approaches	Prasanth Puthanveetil, PhD Assistant Professor, Pharmacology, Midwestern University
21-Feb	On Demand	Biomarker Applications	Validation of a hyperplex assay for single cell spatial analysis of multiple protein and RNA biomarkers within the tumor microenvironment (TME)	Courtney Todorov, PhD Senior Scientist, Scientific Manager Multiplexing, NeoGenomics Laboratories, Inc.